688189 南新製藥
按盤價 
14.730 -0.680 (-4.413%) | 2025/06 - 中期 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -4.369 | -31.865 | -0.830 | -5.823 | -10.832 |
| 總資產報酬率 ROA (%) | -3.491 | -24.264 | -0.592 | -3.859 | -7.678 |
| 投入資產回報率 ROIC (%) | -3.629 | -25.479 | -0.618 | -4.094 | -8.237 | 邊際利潤分析 |
| 銷售毛利率 (%) | 40.881 | 54.591 | 84.475 | 85.788 | 87.125 |
| 營業利潤率 (%) | -71.067 | -147.393 | -1.296 | -10.512 | -28.852 |
| 息稅前利潤/營業總收入 (%) | -72.719 | -148.165 | -0.576 | -9.810 | -28.734 |
| 淨利潤/營業總收入 (%) | -70.864 | -150.891 | -1.499 | -13.968 | -24.539 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 72.305 | 16.838 | -1,042.214 | -52.660 | 46.545 |
| 價值變動淨收益/利潤總額(%) | 0.626 | 0.000 | 163.159 | 7.610 | -1.551 |
| 營業外收支淨額/利潤總額(%) | 0.037 | 0.148 | -2.134 | 0.739 | 0.105 | 償債能力分析 |
| 流動比率 (X) | 2.582 | 2.290 | 2.971 | 2.308 | 2.391 |
| 速動比率 (X) | 2.344 | 2.110 | 2.900 | 2.266 | 2.300 |
| 資產負債率 (%) | 22.168 | 28.151 | 25.230 | 33.676 | 34.582 |
| 帶息債務/全部投入資本 (%) | 14.140 | 18.784 | 20.318 | 29.321 | 28.971 |
| 股東權益/帶息債務 (%) | 604.656 | 430.395 | 390.453 | 239.254 | 243.183 |
| 股東權益/負債合計 (%) | 377.297 | 272.160 | 300.481 | 199.680 | 189.065 |
| 利息保障倍數 (X) | 44.731 | 267.428 | -0.831 | -12.573 | -194.419 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 397.870 | 489.690 | 312.189 | 339.743 | 297.907 |
| 存貨周轉天數 (天) | 287.512 | 137.810 | 92.393 | 160.282 | 215.745 |
| 備註： | 即時報價更新時間為 29/08/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
